11:16 AM EDT, 04/26/2024 (MT Newswires) -- PTC Therapeutics ( PTCT ) shares were up nearly 13% in recent trading on Friday, a day after the company posted Q1 results ahead of consensus.

The company reported Q1 net loss Thursday of $1.20 per diluted share, compared with a loss of $1.88 a year ago.

Analysts polled by Capital IQ expected a loss of $1.27.

Revenue for the quarter that ended March 31 was $177.6 million, down from $187.6 million a year earlier.

Analysts surveyed by Capital IQ expected $172.1 million.

The company reaffirmed its full-year 2024 revenue guidance of between $600 million and $680 million. Analysts polled by Capital IQ expect $663.4 million.

Price: 28.92, Change: +3.43, Percent Change: +13.46